Nebenwirkungen · Tamiflu
Tamiflu 6 mg/ml powder for oral suspension · Abschnitt 4.8 · PDF-Seite 36
HOS-110070 · Präparat HOS-093293
In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and vomiting in the treatment studies, and nausea in the prevention studies. The majority of these ARs were reported on a single occasion on either the first or second treatment day and resolved spontaneously within 1-2 days. In children, the most commonly reported adverse reaction was vomiting. In the majority of patients, these ARs did not lead to discontinuation of Tamiflu.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage e8895edefeffa90248f323172bbc450d606c50f7d0f998003054c7738a085b78 · Zeichen 641–1106 im Abschnitt